Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1819479 dose-finding in idiopathic pulmonary fibrosis (IPF)
CTR20242929Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BI1819479 in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Started Aug 2024; status: completed.
02
Drugs
BI1819479
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20242929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242929.